Shorter overall survival and disease-free survival are related to tumor heterogeneity, with the expression of hormone receptors, such as the human epidermal receptor 2 (HER2+), progesterone receptors (PR+) and estrogen receptors (ER+), determining the molecular subtypes of BC (Figure 1) [9,10]. This evidence concerns the gene PGR and breast cancer.